An updated patent review of Akt inhibitors (2020-present).

In recent years, some combination therapeutic strategies involvingAkt inhibitors have shown promising clinical outcomes. Futureresearch can be directed toward developing new applications of Aktinhibitors, which may have implications for other diseases beyondcancer. New attempts suggest that targeting allosteric sites may be apotential solution to the problem of isoform selectivity.Furthermore, directly knocking out Akt protein by using the degraderssuggests a promising direction for future development.